Teckro Adds Clinical Operations Leader Dana Poff As Chief Operating Officer

Published: Sep 26, 2017

LIMERICK, Ireland--(BUSINESS WIRE)--Teckro, a global life sciences technology company, has named Dana Poff as chief operating officer, adding unparalleled expertise in clinical research services to its growing team.

With more than 28 years of combined health care and clinical research experience, Poff joins Teckro from ICON, a global clinical research organization where she held senior global leadership roles in clinical operations, project management and alliance management. In her most recent role, she served as chief of staff reporting to the CEO.

“I am excited to be part of an organization focused on simplifying the approach to conducting clinical trials and reducing the burden on sites and patients,” said Poff. “I look forward to helping Teckro continue to build upon its significant clinical expertise that allows it to be a market leader in this space.”

“Dana’s knowledge and experience of managing global clinical trials is matched only by her energy and passion for making things better,” said Gary Hughes, Teckro co-founder and CEO. “She is a key addition to our leadership team and will have a big part to play in delivering solutions for our clients, global research sites and patients.”

Poff’s appointment comes on the back of the company raising $10 million in Series B financing, led by Sands Capital Ventures with participation from Bill Maris’ Section 32 venture fund, Founders Fund and private investors. The company has raised $17.8 million to date.

Teckro uses information retrieval and machine learning technologies to improve the speed and accuracy of clinical trial conduct. The Teckro digital platform is deployed at thousands of research sites in over 30 countries across multiple phases of clinical trials, including critical Phase III studies.

About Teckro

Teckro partners with leading pharmaceutical and biotech companies and research institutions to simplify the clinical development process — a recognized bottleneck in the effort to bring new, safe and effective drugs to market. Further details are available at www.teckro.com.

SCORR Marketing
Lea Studer, +1 402.366.1752

Back to news